Targeting hypertension with a new adenosine triphosphate-sensitive potassium channel opener iptakalim

Journal of Cardiovascular Pharmacology

Volumn 56, Issue 3, 2010, Pages 215-228

  Pan, Zhiyuan ^a   Huang, Jinghui ^a   Cui, Wenyu ^a,b   Long, Chaoliang ^a   Zhang, Yanfang ^a,b   Wang, Hai ^a,b,c  

^a BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

^b Thadweik Academy of Medicine   (China)

^c BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

antihypertensive drug; ATP sensitive potassium channel; endothelial dysfunction; hypertension; iptakalim; SUR2B Kir6.1

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; CALCIUM ION; DIAZOXIDE; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.1; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; IPTAKALIM; NIMODIPINE; PINACIDIL;

ALLOSTERISM; ANTIHYPERTENSIVE ACTIVITY; ARTERIOLE; ARTERY; BINDING SITE; BLOOD PRESSURE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CAPACITANCE BLOOD VESSEL; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CHINA; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CYTOPLASM; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; ENDOTHELIUM INJURY; HEART FAILURE; HEART HYPERTROPHY; HUMAN; HYPERTENSION; NEUROLOGIC DISEASE; NONHUMAN; OOCYTE; PRIORITY JOURNAL; REVIEW; RODENT; SMOOTH MUSCLE FIBER; STRUCTURE ACTIVITY RELATION; TARGET ORGAN; VASODILATATION; XENOPUS;

ANIMALS; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; KATP CHANNELS; POTASSIUM CHANNELS, INWARDLY RECTIFYING; PROPYLAMINES;

EID: 77957603729     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181e23e2b     Document Type: Review

References (53)

1. + channels as therapeutic drug targets. Pharmacol Ther. 2002;94:157-182.
2. ATP channels as molecular sensors of cellular metabolism. Nature. 2006;440,470-476.
3. Ueda K, Komine J, Matsuo M., et al Cooperative binding of ATP and MgADP in the sulfonylurea receptor is modulated by glibenclamide. Proc Natl Acad Sci U S A. 1999;96:1268-1272.
4. + channels openers. Pharmacol Ther. 2000;85:39-53.
5. + channels, Neuron. 1996;16:1011-1017.
6. ATP) expressed in guinea pig bladder smooth muscle cells. J Pharmacol Exp Ther. 1999;289:551-558.
7. ATP channel in human corporal smooth muscle cells. Int J Impot Res. 2003;15:258-266.
8. + channels in rat vascular smooth muscles. Biochem Biophys Res Commun. 2002;29: 463-469.
9. Mitsuhiko Y, Shojiro I, Shigeto M., et al Sulphonylurea receptor 2B and Kir6.1 form a sulphonylurea-sensitive but ATP-insensitive K+ channel. J Physiol. 1997;499:715-720.
10. Zhang HL, Bolton TB Two types of ATP-sensitive potassium channels in rat portal vein smooth muscle cells. Br J Pharmacol. 1996;118:105-114.
11. ATP channel: relation with cell metabolism and role in the cardiovascular system. Int J Biochem Cell Biol. 2005;37:751-764.
12. + channels in arterial smooth muscle. Science. 1989;245:177-180.
13. Gribble FM, Tucker SJ, Ashcroft FM The essential role of the Walker A motifs of SUR1 in K-ATP channel activation by Mg-ADP and diazoxide. EMBO J. 1997;16:1145-1152.
14. Abate G, Zito M, Carbonin P.U., et al Pinacidil and hydrochlorothiazide alone or in combination in the treatment of hypertension in the elderly. Curr Ther Res. 1998;59:62-71.
15. Degaute JP, Leeman M, Messin R., et al Treatment of mild-to-moderate arterial hypertension with pinacidil alone or in combination with hydrochlorothiazide. Curr Ther Res. 1998;59:269-274.
16. + channel as a new molecular target for development of antihypertensive drugs. Acta Pharmacol Sin. 1998;19:397-402.
17. Lawson K. Potassium channel activation: a potential therapeutic approach. Pharmacol Ther. 1996;70:39-63.
18. Julius S. Worldwide trends and shortcomings in the treatment of hypertension. Am J Hypertens. 2000;13:S57-S61.
19. Wang H, Tang Y, Wang L., et al ATP-sensitive potassium channel openers and 2,3-dimethyl-2-butylamine derivatives. Curr Med Chem. 2007;14: 133-155.
20. Wang H, Long CL, Zhang YL A new ATP-sensitive potassium channel opener reduces blood pressure and reverses cardiovascular remodeling in experimental hypertension. J Pharmacol Exp Ther. 2005;312:1326-1333.
21. Wang H. Pharmacological characteristics of the novel antihypertensive drug, iptakalim hydrochloride, and its molecular mechanisms. Drug Dev Res. 2003;58:65-68.
22. Coleman MD, Simpson J, Jacobus DP Reduction of dapsone hydroxyl-amine to dapsone during methaemoglobin formation in human erythro-cytes in vitro. III: effect of diabetes. Biochem Pharmacol. 1994;48: 1341-1347. (Pubitemid 24318136)
23. Gribble FM, Ashcroft FM Tissue-specific effects of sulfonylureas: lessons from studies of cloned K(ATP) channels. J Diabetes Complications. 2000;14:192-196.
24. ATP channels. Chin Pharmacol Bull. 2006;22:278-284.
25. ATPchannels and increases insulin release. J Pharmacol Exp Ther. 2007;322: 871-878.
26. Whiteaker KL, Davis-Taber R, Scott VES, et al Fluorescence-based functional assay for sarcolemmal ATP-sensitive potassium channel activation in cultured neonatal rat ventricular myocytes. J Pharmacol Toxicol Methods. 2001;46:45-50.
27. Keimann F, Dribble F, Ashcroft F. Differential response of K(ATP) channels containing SUR2A or SUR2B subunits to nucleotides and pinacidil. Mol Pharmacol. 2000;8:1318-1325.
28. ATPchannel openers. J Mol Cell Cardiol. 2005;38:951-963.
29. + channels and inhibiting insulin release. Diabetologia. 2000;43:723-732.
30. Jiang YG, Yin XF, Wang H. Effects of iptakalim hydrochloride on potassium currents in artery smooth muscles. Chin Pharmacol Bull. 2003; 19:540-547.
31. 3H] glibenclamide in rat aorta and cardiac ventricular membranes. J Cardiovasc Pharmacol. 2001;37:522-531.
32. 3H]P1075 binding with ATP-sensitive potassium channels in artery smooth muscles. Chin J Clin Pharmacol Ther. 2004;9:35-38.
33. 3H] glibenclamide binding with ATP-sensitive potassium channels in artery smooth muscles and its crosstalk with nucleotides. Chin Pharmacol Bull. 2004;20: 402-408.
34. Jia GD, Liu GS, Wang H. Vasodilating characteristics of iptakalim hydrochloride. Med J Chin PLA. 2004;29:116-119.
35. Jia GD, Cui WY, Long C.L., et al Selective vasodilating action in small artery and its pharmacological mechanism of novel antihypertensive drug iptakalim hydrochloride. Chin J Clin Pharmacol Ther. 2004;9:140-145.
36. Gao M, Wang Y, Wang H. Relaxation selectivity of three structurally diverse ATP-sensitive potassium channel openers, iptakalim, pinacidil, and diazoxide on non-vascular smooth muscles. Chin J Clin Pharmacol Ther. 2005;10:633-636.
37. ATP channel opener, in cultured rabbit pulmonary arterial smooth muscle cells. Eur J Pharmacol. 2005;511:81-87.
38. ATP channel. Vascul Pharmacol. 2008;48:92-99
39. Long CL, Zhu QL, Wang A.P., et al Study on selective antihypertensive effects of iptakalim hydrochloride. Chin J Clin Pharmacol Ther. 2003;8: 494-498.
40. ATP activation prevents progression of cardiac hypertrophy to failure induced by pressure overload via protecting endothelial function. Cardiovasc Res. 2009;83:444-456.
41. Long CL, Xiao WB, Wang H. Effects of iptakalim hydrochloride on hypertensive vascular remodeling. Chin J Hypertens. 2003;11:248-250.
42. Xie WP, Wang H, Li B.Z., et al Effects of iptakalim, a novel ATP-sensitive potassium channel opener, on hypoxia-induced pulmonary vascular remodeling in rats. Chin J Appl Physiol. 2003;19:4-7.
43. Zhu HL, Luo WQ, Wang H. Iptakalim protects against hypoxic brain injury through multiple pathways associated with ATP-sensitive potassium channels. Neurosci. 2008;157,884-894.
44. Wang H, Yang RF, Long C.L., et al The novel amine derivatives against ischemia-induced neural damage and their pharmaceutical application. Chin Patents: CN1365966A.
45. Wang H, Zhang YL, Tang X.C., et al Targeting ischemic stroke with a novel opener of ATP-sensitive potassium channels in the brain. Mol Pharmacol. 2004;66:1160-1168.
46. Xue H, Zhang YL, Liu G.S., et al A new ATP-sensitive potassium channel opener protects the kidney from hypertensive damage in experimental hypertension. J Pharmacol Exp Ther. 2005;315:501-509.
47. Long CL, Qin XC, Pan Z.Y., et al Activation of ATP-sensitive potassium channels protects vascular endothelial cells from hypertension and renal injury induced by hyperuricemia. J Hypertens. 2008;26: 2326-2338.
48. Minamino T, Hori M. Protecting endothelial function: a novel therapeutic target of ATP-sensitive potassium channel openers. Cardiovasc Res. 2007; 73:448-449.
49. Costa AD. Iptakalim: a new or just another KCO? Cardiovasc Res. 2009; 83:417-418.
50. Wang H, Long CL, Duan Z.B., et al A new ATP-sensitive potassium channel opener protects endothelial function in cultured aortic endothelial cells. Cardiovasc Res. 2007;73:497-503.
51. Chen YP, Qiu CR, Wang H. Cardiovascular pharmacologicalcharacterization of novel 2,3-dimethyl-2-butylamine derivatives in rats. Life Sci. 2004;75: 2131-2142.
52. Chen YP, Pan ZY, Cui W.Y., et al Selectivity of new iptakalim derivatives on the subtypes of ATP-sensitive potassium channels. Chin Pharmacol Bull. 2008;24:1427-1430.
53. Tang Y, Wang RH, Pan Z.Y., et al The cardiovascular actions of natakalim, a highly selective opener of SUR2B/Kir6.1 subtype of ATP-sensitive potassium channels. Chin Pharmacol Bull. 2009;25: 164-168.